Abiraterone Acetate (CB7630) Phase II Data Released At The ASCO Annual Meeting

At the ASCO Annual meeting in Orlando Florida, Cougar Biotechnology, Inc. announced perliminary results from their ongoing Phase II clinical trials of their much discussed investigational drug abiraterone acetate (CB7630). The company released some preliminary encouraging data in three separate poster presentations. First, I want to tell you what abiraterone acetate is. In scientific jargon [...]

Late Stage Clinical Trials

I compiled a list of trials that are activily recruiting men with hormone refractory prostate cancer (HRPC) who have also failed chemotherapy (taxotere). Being at this point in the disease process is by far the scariest time. We face the reality that there are no more approved treatments available to control the cancer. Clinical trials [...]

Time to Biochemical Failure and PSADT As Prognosticators To Metastatic Disease

A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael B. Williams, MD, et al. presented at the American Urological Association Mid-Atlantic Section - 67th Annual Meeting - October 1 [...]

Go to Top